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e-mail address: elasri_76@hotmail.com (E.A. Fouad).El Asri Fouad ⇑, Momen Hanane, Belmalih Mounir, Zarrouk Rachid, Reda Karim, Oubaaz AbdelberAbstractSystemic lupus erythematosus (SLE) is a chronic, autoimmune, multisystem disease which may affect the eyes and/or visual system
in up to a third of patients. Severe retinal vaso-occlusive diseases have been rarely reported as manifestation in patients with SLE.
We report the case of a 35-year-old female treated for systemic lupus erythematosus for 6 months, presented a sudden loss of
vision. Fundus examination and fluorescein angiography revealed severe retinal vascular occlusion. This has motivated the search
for antiphospholipid antibody syndrome and this was confirmed without the presence of anticardiolipin antibodies. And the treat-
ment consisted in a laser therapy. The purpose of this case report is to demonstrate that an ocular vascular event can reveal the
disease and that its diagnosis is important because this disease generally affects young people and may endanger ocular and vital
prognosis.
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Systemic lupus erythematosus is a multisystem disease of
unknown etiology characterized by numerous autoimmune
phenomena with lesions in multiple organ systems. Ocular
manifestations of systemic lupus erythematosus (SLE) include
mucocutaneous involvement of the eyelids, secondary Sjo-
gren’s syndrome, optic neuropathy. The retinopathy gener-
ally consists of cotton wool spots with or without retinal
hemorrhages.1–3
Vaso-occlusive disease, particularly in the presence of
antiphospholipid antibodies, usually cause devastating and
permanent damage to visual function in spite of vigorous
treatment and requires treatment with anticoagulation
and proliferative retinopathy is treated with laser
therapy.2,3Case report
A 35-year-old woman was admitted because of sudden
decrease of visual acuity in the left eye. She had been diag-
nosed as suffering from systemic lupus erythematosus
6 months ago on the basis of oral ulcers, and general aching
and malar rashes on her face and immunological disorder and
antinuclear antibody according to the criteria of the revised
American College of Rheumatology. She was treated with
oral prednisone (60 mg per day) and hydroxychloroquine
400 mg/day.
At presentation she underwent a complete ophthalmolog-
ical examination. Visual acuity was no light perception in the
left eye. Examination of the anterior segment was normal and
the lens was clear. The ophthalmoscopic examination with
mydriasis showed severe ischemic retinopathy in the lefte:
al.com
.: +212
Figure 2. Retinal fluorescein angiography showed ischemic retinopathy
and papillary neovascularisation.
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cein angiography showed ischemic retinopathy and con-
firmed the papillary neovascularisation (Fig. 2).
The visual acuity of her right eye was 20/20, with a normal
anterior segment and fundus (Fig. 3). The bilateral intraocular
pressures (IOP) were both 12 mmHg. Laboratory evaluation
revealed abnormal titers of antinuclear antibodies, increased
level of erythrocyte sedimentation rate and IgG, with low C3
and C4 complement levels.
On the other hand, the levels of antiphospholipid antibod-
ies (APAs) (including lupus anti-coagulant, anti-cardiolipin
and anti-beta2 glycoprotein 1 antibodies), blood lipid,
screening for thrombophilia were within normal range. Car-
diovascular evaluation (including electrocardiogram, heart
color ultrasound, carotid Doppler and head CT) were normal.
These features suggested the clinical diagnosis of vaso-
occlusive disease secondary to ocular SLE. The treatment
consists in a Panretinal argon laser photocoagulation on the
second day after admission but a week later, the patient
had a vitreous hemorrhage secondary to neovascularization.Figure 3. fundus of the right eye was normal.Discussion
SLE is an autoimmune inflammatory disease characterized
by numerous autoimmune phenomena with lesions in multi-
ple organ systems. The thrombotic and inflammatory process
can affect any part of the eye and result in manifestations
such as keratoconjunctivitis, scleritis, uveitis and ischemic
optic neuropathy.1–3
Most common retinal findings in SLE are cotton-wool
spots, hemorrhage, and vascular abnormalities, these lesions
occur in 3% to 29% of cases and generally are found late in
the disease. The underlying disease involves microvascular
occlusion mediated by circulating immune complexes caus-
ing retinal nerve fiber layer infarction.1,2 By contrast, a less
common but more severe form of ocular disease in SLE is
occlusive ocular vascular disease. The process is generally
one of diffuse arteriolar occlusion with extensive capillary
non-perfusion. After such extensive ischemia various conse-
quences of neovascularisation, such as vitreous hemorrhage,
traction retinal detachment, and thrombotic glaucoma, may
occur.1–4
The pathogenesis of SLE is the production of
autoantibodies against cellular components and formingFigure 1. Fundus of the left eye showed severe ischemic retinopathy in
the left eye with papillary neovascularisation.immune-complex deposition in the end-organ. The activation
of complement and inflammatory cells induces tissue dam-
age and systemic disease. Severe vaso-occlusive retinopathy
is classically a microangiopathy with diffuse capillary non-per-
fusion and small arterial or arteriolar occlusions in the retina.
It is typically characterized by microthrombosis and immune
complex mediated vasculopathy rather than vasculitis.2–5
A higher risk of developing ocular vascular occlusion is
usually indicated in SLE patients with increased serum con-
centrations of APAs such as the lupus anticoagulant and anti-
cardiolipin antibodies. However, low APAs level may
occasionally occur in patients of retinal vaso-occlusive retinal
disease.3–5
The clinical significance of the lupus anticoagulant and
related antiphospholipid antibodies in patients with SLE are
their association with thrombotic events, recurrent fetal wast-
age and thrombocytopenia. The frequency of the lupus anti-
coagulant or related antiphospholipid antibodies in patient
with SLE has been estimated to be 6.7% to 25%.5,6 The differ-
ences in incidence of lupus anticoagulants and anticardiolipin
antibodies in SLE is not merely a matter of test sensitivities.
Poor visual prognosis is reported in SLE retinopathy with
visual loss in 80% of cases and neovascularization in 40% of
cases. The permanent loss of visual acuity is likely due to
retinal ischemia.3,7 The mainstay of treatment for significant
retinal disease is systemic immunosuppression. In unilateral
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sometimes used in addition.
In the presence of significant vaso-occlusive disease (par-
ticularly when APA are present), anti-coagulation and the
addition of low dose acetylsalicylic acid may be beneficial.
Proliferative retinopathy usually requires treatment with laser
(panretinal photocoagulation) akin to the treatment of prolif-
erative diabetic retinopathy.2,4
Other therapies that have been reported for severe dis-
ease include plasmapheresis and plasma exchange, intravi-
treal antivascular endothelial growth factor agents, and
vitrectomy may also be considered for the treatment of com-
plications of ocular ischemia.6–8
Retinal disease affects around 10% of SLE patients, reflect-
ing a reduction in frequency associated with improved con-
trol of systemic disease. Such visual symptoms are
therefore an indication for urgent ophthalmic review. The ret-
inal signs often parallel the severity of systemic inflammation,
and may indicate inadequate control of the systemic disease.
The presence of APA is associated with more severe retinop-
athy and vascular occlusions.
Conclusion
The presence of retinopathy is suggestive of high disease
activity during the history of SLE and may reflect systemic,
particularly vascular damage. Close communication between
the consultant ophthalmologist and treating rheumatologistis critical in the effective management of these complex clin-
ical situations.
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